NEW ZEALAND GAZETTE, No. 39

17 FEBRUARY 2005

1012

mean low-water mark (37°33.6′S 178°19.5′E), then generally
south-west along that 200 metre limit to a point due south
of the western end of the Hicks Bay Wharf (37°34.1′S
178°18.0′E), then due north to the western end of the Hicks
Bay Wharf on the coastline (37°34.3′S 178°18.0′E), then
proceeding generally north-east following the coastline to
the point of commencement at Matakaoa Point.

(2) The geographical co-ordinates set out in subclause (1)
are expressed in terms of WGS84 datum.

Dated at Wellington this 10th day of February 2005.

DAVID BENSON-POPE, Minister of Fisheries.

Explanatory Note

This note is not part of the notice, but is intended to indicate
its general effect.

This notice, which comes into force on 18 February 2005,
imposes a ban on taking shellfish (including rock lobster
and kina) from an area at Hicks Bay for a two-year period
from 18 February 2005 to 17 February 2007.

It is similar to and takes over from a previous notice that
imposed a ban on the taking of shellfish in the same area
from 8 February 2003 to 7 February 2005.

go921

Health

Medicines Act 1981

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the new medicine set out in the Schedule hereto:

Schedule

Product:
Ferro-Liquid

Active Ingredient:
Ferrous sulphate 30mg

Dosage Form:
Oral solution

New Zealand Sponsor:
AFT Pharmaceuticals Limited

Manufacturer:
Pharmascience Inc, Montreal, Quebec, Canada

Dated this 11th day of February 2005.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go913

Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set
out in the Schedule hereto:

Schedule

Product:
Mabthera

Active Ingredient:
Rituximab 10mg/mL

Dosage Form:
Concentrate for infusion

New Zealand Sponsor:
Roche Products (New Zealand) Limited

Manufacturers:
F Hoffmann-La Roche Limited, Basel, Switzerland
Genentech Inc, South San Francisco, California, United States of America

Dated this 11th day of February 2005.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go914

New Zealand Public Health and Disability Act 2000

Reappointment/appointments to District Health Boards

Pursuant to section 29 (1) (b) of, and clause 2 of Schedule 3 to, the New Zealand Public Health and Disability Act 2000
and notice to the member under section 28 (2) of the Crown Entities Act 2004, I have reappointed

Airini Pirihira Tukerangi

as a member of the board of Counties Manukau District Health Board.

Pursuant to section 29 (1) (b) of the New Zealand Public Health and Disability Act 2000 and notice to the member
under section 28 (2) of the Crown Entities Act 2004, I have appointed

Gordon Joseph Blake
Michelle Taina Nathan

as members of the board of Waikato District Health Board.

The reappointment and appointments above take effect on
14 February 2005 and will end on 9 December 2007.

Dated at Wellington this 9th day of February 2005.

ANNETTE KING, Minister of Health.

go909